Autosomal recessive congenital bilateral absence of vas deferens is a genetic condition that affects the tubes that carry sperm from the testes. People with this condition typically have no sperm in the semen and may notice infertility as the first sign. It is lifelong and usually recognized in late teens or adulthood when pregnancy does not happen. Not everyone will have the same experience, and some may have related features such as mild respiratory or sinus issues if linked with CFTR variants. Treatment focuses on fertility options like sperm retrieval with IVF/ICSI, and life expectancy is typical when no severe related health problems are present.
Overview
Autosomal recessive congenital bilateral absence of vas deferensSymptoms
Most people notice no day-to-day problems. Autosomal recessive congenital bilateral absence of the vas deferens usually shows up during fertility testing as trouble conceiving, very low semen volume, and no sperm in semen; doctors feel missing vas tubes on exam.
Outlook and prognosis
Most people with autosomal recessive congenital bilateral absence of the vas deferens (CBAVD) are healthy overall and have normal sexual function. Fertility is affected, but assisted options like sperm retrieval with IVF/ICSI help many build families. Lifespan isn’t typically shortened.
Causes and risk factors
Autosomal recessive congenital bilateral absence of vas deferens stems from inherited changes in the CFTR gene. It develops before birth; lifestyle factors don’t cause it. Risk rises when both parents are carriers, with family history or close relatedness.
Genetic influences
Genetics are central in Autosomal recessive congenital bilateral absence of vas deferens. Most cases involve pathogenic CFTR variants; some also include modifier genes that influence severity and fertility options. Family history and carrier testing guide counseling, reproductive planning, and partner screening.
Diagnosis
Doctors suspect it during infertility evaluation when semen shows no sperm and the vas deferens isn’t felt. Confirmation uses ultrasound or MRI and semen testing. Genetic diagnosis of Autosomal recessive congenital bilateral absence of vas deferens includes CFTR testing.
Treatment and drugs
Treatment for autosomal recessive congenital bilateral absence of the vas deferens focuses on family-building and related health checks. Many pursue sperm retrieval with IVF/ICSI, sometimes using testicular sperm. Care often includes genetic counseling, CFTR testing, and screening for subtle lung or sinus issues.
Symptoms
People living with autosomal recessive congenital bilateral absence of the vas deferens (often shortened to CBAVD) usually feel well and have a normal sex life. Early on, this might look like having a typical sex life but facing unexpected trouble conceiving with a partner. The condition’s features mostly stem from semen containing little or no sperm because the sperm-carrying tubes are missing from birth. Early features of autosomal recessive congenital bilateral absence of vas deferens often come to light during fertility testing rather than day-to-day symptoms.
Many discover CBAVD during a fertility workup after months of trying without pregnancy. The missing tubes prevent sperm from entering the semen even when the testes make healthy sperm.
Ejaculate may look small in amount and thinner or watery. This reflects reduced fluid from the glands that usually add most of the semen.
A semen analysis often shows no sperm in the sample. Clinicians call this azoospermia, which means no sperm are seen under the microscope.
Desire, erections, and orgasm are typically normal. This contrast—normal sex with infertility—can be confusing until testing explains the cause.
How people usually first notice Autosomal recessive congenital bilateral absence of vas deferens?
Many first notice something is off when they try to conceive and a routine semen analysis shows very low or zero sperm despite normal sexual function; this often leads to the diagnosis of the first signs of Autosomal recessive congenital bilateral absence of vas deferens (CBAVD). Some are flagged earlier because of a personal or family history of cystic fibrosis, or because newborn screening or early childhood breathing and sinus issues prompt CF carrier testing that later explains how CBAVD is first noticed in adulthood. Doctors typically confirm the cause with a physical exam showing absent or very small vas deferens and genetic testing for CFTR variants, which helps explain why sperm can’t travel out of the testes even though sperm production is often normal.
Types of Autosomal recessive congenital bilateral absence of vas deferens
Autosomal recessive congenital bilateral absence of vas deferens (CBAVD) has a few well-recognized genetic variants that can influence how it shows up and what else may be involved. Many living with CBAVD notice infertility first, then learn through testing that certain gene changes are responsible. Clinicians often describe them in these categories: CFTR-related forms, ADGRG2-related forms, and rarer, less defined genetic causes. Not everyone will experience every type.
CFTR-related CBAVD
Changes in the CFTR gene lead to missing or blocked vas deferens with normal testicular function. Symptoms don’t always look the same for everyone. Some have only infertility, while others have mild features linked to cystic fibrosis such as sinus issues or thicker mucus.
ADGRG2-related CBAVD
Variants in the ADGRG2 gene cause CBAVD, typically inherited in an X-linked pattern. People may notice different sets of symptoms depending on their situation. This type usually presents with infertility in otherwise healthy men and may be found when CFTR testing is negative.
Undetermined genetic causes
A smaller group has CBAVD without identifiable CFTR or ADGRG2 variants. For many, certain types stand out more than others. These variants of CBAVD are still being studied, and testing may expand over time to clarify the types of CBAVD.
What genetics can tell you about symptoms
Certain CFTR gene variants disrupt chloride channels in the reproductive tract, so the vas deferens doesn’t form, leading to absent sperm in the ejaculate (azoospermia) and infertility. Some men also have thicker mucus, mild respiratory symptoms, or sinus issues, depending on the specific variants.
Causes and risk factors
In autosomal recessive congenital bilateral absence of vas deferens, the main cause is inherited changes in the CFTR gene, and rare changes in other genes can play a role. Some risks are written in our DNA, passed down through families. Risk is higher when both parents carry CFTR changes or there is a family history, and it can be higher when parents are related. Pregnancy exposures and adult lifestyle do not cause the ducts to be absent, but general reproductive health issues can still affect fertility planning. Carrier frequency varies by ancestry, so risk factors for autosomal recessive congenital bilateral absence of vas deferens depend on family background.
Environmental and biological risk factors
This section looks at things in the body and the environment that might change the chance of autosomal recessive congenital bilateral absence of vas deferens. Evidence on environmental risk factors for autosomal recessive congenital bilateral absence of vas deferens is limited. Researchers are still exploring how outside influences interact with our inner biology. Below, we note what’s known and, just as important, what hasn’t been shown.
No specific environmental chemical, radiation level, or pollutant has been consistently linked to autosomal recessive congenital bilateral absence of vas deferens. Studies in humans have not shown a repeatable pattern of risk.
Advanced maternal or paternal age does not appear to increase risk. Rates of this congenital finding have not been tied to parents’ ages.
Common maternal conditions such as diabetes, thyroid disease, or high blood pressure have not been shown to raise the chance of autosomal recessive congenital bilateral absence of vas deferens. When present, these conditions are linked with other birth outcomes, not this specific duct development issue.
No clear link has been found between typical viral or bacterial infections during pregnancy and this condition. Available data do not show a consistent pattern.
Genetic risk factors
Autosomal recessive congenital bilateral absence of vas deferens (CBAVD) is most often linked to changes in the CFTR gene, the same gene involved in cystic fibrosis. These genetic causes of congenital bilateral absence of the vas deferens usually lower CFTR activity rather than shut it off completely, which is why many have normal lungs and pancreas. Carrying a genetic change doesn’t guarantee the condition will appear. Other, less common gene changes, such as in ADGRG2, and family patterns can also shape who develops this condition.
CFTR variants: Changes in the CFTR gene are the leading genetic cause of CBAVD. They reduce chloride channel function in the reproductive tract, blocking the vas deferens from forming.
5T/TG modifiers: A common CFTR splicing change called the 5T allele, especially when paired with longer TG repeats, can tip the balance toward CBAVD. On its own it may be silent, but combined with another CFTR variant it increases the chance the ducts don’t develop.
Two-hit pattern: Most affected men carry two CFTR changes, often a milder one paired with a typical disease-causing one. One change alone usually does not cause obstructive infertility.
Family history: Relatives with cystic fibrosis or obstructive infertility suggest shared CFTR variants are present in the family. Because inheritance is usually autosomal recessive, parents are typically healthy carriers.
ADGRG2 changes: Rare changes in the X-linked ADGRG2 gene can cause CBAVD when CFTR testing is negative. This pattern may affect males in the maternal line and spare most females.
Ancestry patterns: The types of CFTR variants differ by ancestry, which can change how likely a specific test will find them. This helps explain why detection rates and residual risk estimates vary between populations.
Lifestyle risk factors
This condition is present from birth and is not caused by lifestyle. However, how lifestyle affects Autosomal recessive congenital bilateral absence of vas deferens is mainly through its impact on sperm production in the testes, sexual health, and the success of assisted reproductive options like surgical sperm retrieval with IVF/ICSI. The elements below focus on habits that can influence sperm retrieval quality, readiness for procedures, and any CFTR‑related symptoms that may coexist.
Smoking can impair spermatogenesis and increase sperm DNA damage, which may reduce the quality and yield of testicular/epididymal sperm for ICSI. It may also worsen CFTR‑related airway issues in those with CBAVD linked to CFTR variants.
Testosterone or anabolic steroid use suppresses the pituitary–testis axis, often causing severe drops in sperm production and compromising sperm retrieval. Recovery can take months after stopping, delaying fertility plans.
Frequent hot tubs, saunas, or prolonged scrotal heat (tight gear, hot cycling seats, laptops on lap) can lower testicular sperm production. This may reduce the number and quality of sperm available during retrieval for IVF/ICSI.
Excess adiposity is associated with lower testosterone and poorer spermatogenesis, which can decrease sperm retrieval rates. Weight reduction and a nutrient-dense diet may improve hormones and ART outcomes in CBAVD.
Risk prevention
For most people, autosomal recessive congenital bilateral absence of vas deferens (CBAVD) isn’t something you can prevent in yourself, because it develops before birth. Prevention focuses on planning and testing to lower the chance of having a child with CBAVD and to spot related issues linked to CFTR gene changes. Knowing your risks can guide which preventive steps matter most. Early symptoms of autosomal recessive congenital bilateral absence of vas deferens are uncommon—many only learn about it during fertility checks in adulthood.
A simple saliva or blood test can check if you carry CFTR changes linked to CBAVD. Screening is most helpful if you have a family history or a partner with CBAVD.
If you have CBAVD or carry a CFTR variant, ask that your partner be tested. When both partners carry CFTR changes, targeted planning can reduce the chance of an affected child.
A genetics professional can explain inheritance, personal risks, and options in clear terms. Counseling also helps you decide which tests and timing fit your plans.
Options like IVF with ICSI can use sperm retrieved directly from the testes or epididymis. Some couples add preimplantation genetic testing (PGT-M) to lower the chance of CBAVD in future children.
Transmission
Autosomal recessive congenital bilateral absence of vas deferens (CBAVD) is not contagious; it’s present from birth and cannot be caught or spread through contact.
The condition is usually linked to changes in the cystic fibrosis (CFTR) gene and follows an autosomal recessive pattern, meaning a child must inherit one altered copy from each parent to be affected. If both partners are carriers, each pregnancy has a 25% (1 in 4) chance that the child will inherit two altered copies; in males, this can lead to CBAVD, and in some families the same gene changes can cause cystic fibrosis. People with CBAVD who are planning a family, including using IVF/ICSI, are often advised to seek genetic counseling and carrier testing for both partners to discuss the genetic transmission of Autosomal recessive congenital bilateral absence of vas deferens.
When to test your genes
Consider genetic testing if you have obstructive azoospermia, low semen volume, or a diagnosis of congenital bilateral absence of the vas deferens (CBAVD), especially when planning a family. Test sooner if you have a personal or family history of CFTR variants or cystic fibrosis symptoms. Results guide fertility options and partner testing to clarify reproductive risks.
Diagnosis
Many first notice something is off when attempts to conceive aren’t working, often alongside very low semen volume. Getting a diagnosis is often a turning point toward answers and support. For autosomal recessive congenital bilateral absence of vas deferens, doctors piece together exam findings, lab results, and imaging with genetic tests. The goal is to confirm the cause of obstructive infertility and guide next steps.
The clinician gently feels the scrotum to check whether the vas deferens cords are present; in this condition they are typically absent on both sides. Testicle size and firmness are usually normal, which points toward a blockage rather than low sperm production.
The lab measures volume, acidity, and whether sperm are present. Results often show very low volume, acidic semen, and no sperm (obstructive azoospermia), supporting congenital absence of the ducts.
Imaging helps confirm that the vas deferens are missing or underdeveloped. It can also look at the epididymis and testicles to rule out other causes of blockage.
This scan looks at the ejaculatory ducts and seminal vesicles. Missing or small seminal vesicles often go along with absent vas deferens and strengthen the diagnosis.
Stages of Autosomal recessive congenital bilateral absence of vas deferens
Autosomal recessive congenital bilateral absence of vas deferens does not have defined progression stages. There are usually no early symptoms of autosomal recessive congenital bilateral absence of vas deferens, and many people only discover it when pregnancy doesn’t happen. Identifying the cause is the starting point for the right care. Diagnosis is based on a fertility history and exam, semen analysis showing little or no sperm, ultrasound to confirm the missing vas deferens, and genetic testing of the CFTR gene; sometimes a partner is also offered testing.
Outlook and prognosis
For many, the most immediate impact of autosomal recessive congenital bilateral absence of vas deferens (CBAVD) is infertility due to blocked sperm transport, not day‑to‑day illness. The outlook is generally favorable for overall health and life span, because CBAVD on its own does not affect breathing, digestion, or heart function. Many people ask, “What does this mean for my future?”, and the answer is often about family‑building options rather than medical complications.
In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Some people with CBAVD carry gene changes linked to cystic fibrosis; when that’s the case, doctors may check for subtle lung or pancreatic issues, though most with isolated CBAVD do not develop classic cystic fibrosis. Mortality is not increased for isolated CBAVD, and long‑term survival matches the general population. Genetic testing can sometimes provide more insight into prognosis, especially if there’s a known family history of cystic fibrosis or related conditions.
Looking at the long-term picture can be helpful. Fertility prospects are strong: sperm are typically made normally in the testes, and many couples achieve pregnancy through procedures like testicular sperm retrieval combined with IVF or ICSI. Over time, most people find their health needs focus on reproductive care, genetic counseling for both partners, and routine health screening like anyone else. Talk with your doctor about what your personal outlook might look like, including early symptoms of CBAVD that might lead to diagnosis—such as low semen volume or infertility—and the best path to parenthood if that’s your goal.
Long-term effects
Autosomal recessive congenital bilateral absence of vas deferens mainly affects fertility over the long term, while overall health and sexual development are typically unaffected. Long-term effects vary widely, and many have no day-to-day health problems beyond reproductive challenges. People rarely notice early symptoms of autosomal recessive congenital bilateral absence of vas deferens, since puberty and sexual function usually develop as expected. Some features relate to CFTR gene changes, which can influence the reproductive tract and, in a minority, the sinuses or pancreas.
Natural conception is not expected because sperm cannot travel out of the testicles. Most people still make sperm in the testicles, but it is blocked from the semen.
Semen volume is often low and typically lacks sperm. It may be more acidic and have low fructose due to underdeveloped seminal vesicles.
Puberty, testosterone levels, and secondary sexual traits usually develop as expected. Erections, ejaculation, and libido are typically normal.
Some people with autosomal recessive congenital bilateral absence of vas deferens have mild features tied to CFTR variants. These can include chronic sinus issues or, less commonly, pancreatitis.
How is it to live with Autosomal recessive congenital bilateral absence of vas deferens?
Living with autosomal recessive congenital bilateral absence of the vas deferens (CBAVD) often means discovering infertility when trying to conceive, despite feeling completely healthy otherwise. Daily life typically isn’t limited physically, but family-building choices come to the forefront—many pursue assisted reproductive options like testicular sperm extraction with IVF, and genetic counseling to understand carrier risks for conditions linked to CFTR variants. Partners may feel the emotional weight too, so open communication and shared decision-making matter; many couples find relief in having clear, practical paths forward. For some, knowing this is a congenital, non-progressive finding brings stability—you can plan once, then live your life fully while revisiting options when you’re ready.
Treatment and drugs
Autosomal recessive congenital bilateral absence of vas deferens (CBAVD) is treated by focusing on fertility options and routine health monitoring rather than trying to regrow the missing ducts. For many people, treatment begins with small daily steps like general testicular health checks and genetic counseling to understand links with cystic fibrosis–related genes and to guide family planning. Sperm can often be retrieved directly from the testes or epididymis with minor procedures and then used with in vitro fertilization and intracytoplasmic sperm injection (IVF/ICSI), which offers high chances of biological parenthood. Your doctor may suggest screening for subtle lung, sinus, or pancreatic features if gene testing shows cystic fibrosis–related variants, and partners are usually offered carrier testing before IVF. Ask your doctor about the best starting point for you, including referral to a reproductive urologist and a fertility clinic experienced with CBAVD.
Non-drug treatment
Treatment focuses on helping you build a family and understanding the genetic background. Non-drug treatments often lay the foundation for care, since surgery usually can’t create a missing vas deferens. Many notice no early symptoms of autosomal recessive congenital bilateral absence of vas deferens until trying to conceive. A team approach with a reproductive urologist, fertility specialist, and genetic counselor is common.
A urologist can collect sperm directly from the testicle or epididymis using needle aspiration or a small surgical procedure. The sperm can be used the same day or frozen for later IVF/ICSI.
Intracytoplasmic sperm injection places a single retrieved sperm into an egg to help fertilization. This approach is typically needed in congenital bilateral absence of the vas deferens because sperm cannot travel out naturally.
A counselor explains how CFTR-related genetics connect to this condition and discusses chances of passing it on. They review testing options and family-building choices tailored to your goals.
Testing your partner for CFTR variants helps clarify the chance of cystic fibrosis or related conditions in future children. Ask your doctor which non-drug options might be most effective for your situation.
Your genes may have an impact on how drugs work for you
Most medicines for autosomal recessive congenital bilateral absence of the vas deferens aren’t “gene-targeted,” but your genes can still shape how your body processes drugs for fertility procedures, infections, or pain. Pharmacogenetic differences may affect dose needs, side‑effects, and success rates.
Pharmacological treatments
Autosomal recessive congenital bilateral absence of vas deferens affects fertility because the ducts that carry sperm out of the testes didn’t form. There are no medications for Autosomal recessive congenital bilateral absence of vas deferens that can rebuild or “open” these missing ducts; treatment usually relies on assisted reproductive techniques. Medicines are used only to manage related issues such as infections, discomfort, or other health needs in those who also have cystic fibrosis features. Medication is often just one chapter, alongside procedures like surgical sperm retrieval with IVF/ICSI and genetic counseling.
No approved medicine can create or restore the vas deferens in AR-CBAVD. Drugs may support comfort or treat infections, but they do not change fertility by themselves.
Elexacaftor/tezacaftor/ivacaftor, ivacaftor, or lumacaftor/ivacaftor may be used if someone also has cystic fibrosis symptoms based on their CFTR variants. These medicines can improve lung and digestive health but do not restore the vas deferens or natural fertility.
Doxycycline, ciprofloxacin, or levofloxacin may be prescribed if epididymal or urinary tract infections occur. Treating infection can ease pain and swelling and protect overall reproductive health.
Ibuprofen or naproxen can reduce inflammation and discomfort, and acetaminophen (paracetamol) can help with pain. These medicines are often used short term, for example after procedures or during an infection flare.
Genetic influences
Genetics plays a central role in this condition. Most cases are tied to changes in the CFTR gene—the same gene associated with cystic fibrosis—and are typically inherited in a recessive way, meaning both copies of the gene are affected; less commonly, other genes may be involved. Many men with these CFTR changes are otherwise healthy and discover them only during an infertility workup. A “carrier” means you hold the gene change but may not show symptoms. Genetic testing for autosomal recessive congenital bilateral absence of vas deferens often focuses on the CFTR gene and can clarify which changes are present and whether a partner carries one too. If a partner also carries a CFTR change, there is a chance to have a child with cystic fibrosis, and a genetics professional can explain the specific risks for your family. Even with similar CFTR changes, features can vary—some people have only absent or blocked sperm ducts, while others have mild sinus or respiratory symptoms.
Is Autosomal recessive congenital bilateral absence of vas deferens genetic?
Genetics are central in Autosomal recessive congenital bilateral absence of vas deferens. Most cases involve pathogenic CFTR variants; some also include modifier genes that influence severity and fertility options. Family history and carrier testing guide counseling, reproductive planning, and partner screening.
Pharmacogenetics—how genetics influence drug effects
There isn’t a medicine that can rebuild the missing vas deferens, so treatment for most people with this condition focuses on surgical sperm retrieval with IVF/ICSI to help achieve pregnancy. Genetics still plays a key role, because many have changes in the CFTR gene, and those results guide counseling and whether to look for subtle cystic fibrosis–related features that might also need care. Alongside your medical history and fertility evaluation, genetic testing can help clarify which CFTR changes you carry and point to the most appropriate care. If CFTR-related lung, sinus, or pancreatic symptoms are present, doctors may consider CFTR modulator medicines, but eligibility and expected benefit depend on the exact variants; these drugs do not reverse congenital absence of the vas deferens. Medicines used around sperm retrieval—such as pain relief or antibiotics—are chosen based on overall health and the procedure plan, rather than on CFTR genotype. Because early symptoms of Autosomal recessive congenital bilateral absence of vas deferens are often limited to trouble conceiving, genetics also shapes family planning, including partner carrier testing and options like IVF with preimplantation testing to reduce the chance of cystic fibrosis in children.
Interactions with other conditions
Autosomal recessive congenital bilateral absence of vas deferens often occurs alongside conditions linked to changes in the CFTR gene, the same gene involved in cystic fibrosis. Many with this diagnosis have no lung or digestive symptoms of cystic fibrosis, but some may notice issues like chronic sinus problems or a history of pancreatitis, which can point to a milder, related CFTR condition. For many, the first clues or early symptoms of autosomal recessive congenital bilateral absence of vas deferens appear during fertility testing, and that workup commonly includes screening for cystic fibrosis in both partners. Shared genetic variants may explain why certain conditions cluster together.
Kidney or urinary tract differences are less common in this condition, but they can be found, so some clinicians recommend a one-time kidney imaging check. Treatments for other illnesses rarely interfere directly, but antibiotics or procedures in the pelvic area can affect the reproductive tract and are worth discussing with a urologist. This connection brings us to how the condition interacts with others: if cystic fibrosis or a CFTR‑related disorder is present, coordinated care with genetics, pulmonology, and fertility specialists helps tailor safe family‑building options. Talk with your doctor about how your conditions may influence each other, including whether your partner should have CFTR testing before assisted reproduction.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns: some men grew up healthy, reached adulthood, and yet could not father children. In some families, brothers shared this experience while sisters did not. Long before modern testing, this raised quiet questions about what was being passed down.
First described in the medical literature as men who produced semen with very low volume and no sperm, the condition gradually became linked to missing tubes that normally carry sperm from the testes. Surgeons and pathologists in the mid-20th century reported that these ducts—the vas deferens—were absent on both sides from birth, a feature now recognized as autosomal recessive congenital bilateral absence of the vas deferens. Early reports focused on what could be seen during surgery or under the microscope, and on the practical problem of infertility.
From early theories to modern research, the story of autosomal recessive congenital bilateral absence of the vas deferens has shifted from anatomy to genes. In the 1980s and 1990s, researchers noticed that many men with this condition shared changes in a gene linked to cystic fibrosis, called CFTR. Some had mild or no lung symptoms, which helped explain why their condition had gone unnoticed until fertility was tested. This moved thinking beyond a simple “missing tubes” description toward a broader understanding of how small changes in fluid balance and development during fetal life can affect the reproductive tract.
With each decade, testing improved. Gentle imaging and scrotal examination confirmed the absence of the vas deferens without surgery, and genetic testing made it possible to identify CFTR variants in many—but not all—affected men. This clarified that autosomal recessive congenital bilateral absence of the vas deferens is often part of the spectrum of CFTR-related conditions, even when breathing and digestion are normal. It also highlighted variability: some men have associated findings such as missing or underdeveloped seminal vesicles, while others do not.
In recent decades, awareness has grown as assisted reproductive technologies advanced. Intracytoplasmic sperm injection (ICSI) allowed sperm retrieved directly from the testes to fertilize an egg, turning a once-insurmountable barrier to conception into a challenge that many couples can overcome. This clinical progress encouraged more systematic evaluation, including partner testing when CFTR variants are found, to inform family planning.
Understanding has continued to mature. Historical differences highlight why careful, person-centered evaluation matters: similar fertility struggles can have different causes, and the label alone does not predict health beyond reproduction. Today, the history of autosomal recessive congenital bilateral absence of the vas deferens is a reminder of how careful observation, anatomy, and genetics came together to explain a quiet, lifelong condition—and to open practical paths to parenthood.